Posted by Michael Wonder on 14 Jan 2019
Life-extending drug Perjeta approved for secondary breast cancer
14 January 2019 - A drug used to treat advanced breast cancer has been approved for use on the NHS in Scotland.
Pertuzumab, trade name Perjeta, can now be used in the treatment of HER2 positive metastatic breast cancer and in aggressive breast cancers which cannot be surgically removed.
The drug was rejected by the Scottish Medicine Consortium three times on cost grounds.
In December it was given the go-ahead for use in early-stage breast cancer.
